Royalty Pharma to buy royalty interest in Amgen's lung cancer drug for up to $950 million
1. Royalty Pharma acquires a royalty interest in Amgen's lung cancer drug. 2. Deal could impact Amgen’s revenue by up to $950 million.
FAQ
Why Bullish?
The acquisition indicates strong market confidence in Amgen’s drug potential, similar to past successful licensing deals, like their collaboration with Bristol-Myers Squibb which boosted stock performance significantly.
How important is it?
This development signals investor confidence in AMGN’s drug pipeline, possibly leading to stock price appreciation as market reacts positively.
Why Short Term?
The immediate revenue boost from the royalty deal will likely affect investor outlook and stock price in the short term, as seen with past pharmaceutical royalty transactions.